These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 15851743)

  • 1. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy.
    Comella CL; Morrissey M; Janko K
    Neurology; 2005 Apr; 64(8):1450-1. PubMed ID: 15851743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A; Sanchez-Ramos J
    Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
    [No Abstract]   [Full Text] [Related]  

  • 3. [Multiple latency test in a patient with episodes of sleep induced by pergolide].
    Jiménez-Jiménez FJ; Velasco I; de Toledo M; Sayed Y; Zurdo J; Ortí-Pareja M
    Rev Neurol; 2002 Jun 16-30; 34(12):1140-1. PubMed ID: 12134281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
    Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
    Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
    de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R
    Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM; Houeto JL
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
    Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J
    Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Grosset K; Needleman F; Macphee G; Grosset D
    Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
    Razmy A; Lang AE; Shapiro CM
    Arch Neurol; 2004 Jan; 61(1):97-102. PubMed ID: 14732626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sleep attacks and pergolide mesylate].
    García Ruiz PJ; Hernández J; Cantarero S; Fanjul S
    Neurologia; 2001 Feb; 16(2):92. PubMed ID: 11257938
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease.
    Paus S; Brecht HM; Köster J; Seeger G; Klockgether T; Wüllner U
    Mov Disord; 2003 Jun; 18(6):659-67. PubMed ID: 12784269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pergolide in late-stage Parkinson disease.
    Lang AE; Quinn N; Brincat S; Marsden CD; Parkes JD
    Ann Neurol; 1982 Sep; 12(3):243-7. PubMed ID: 6753730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from pergolide to pramipexole in patients with Parkinson's disease.
    Hanna PA; Ratkos L; Ondo WG; Jankovic J
    J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nyholm D; Jansson R; Willows T; Remahl IN
    Neurology; 2005 Nov; 65(9):1506-7. PubMed ID: 16275852
    [No Abstract]   [Full Text] [Related]  

  • 18. Medical hazards of the internet: gambling in Parkinson's disease.
    Larner AJ
    Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Nov; 18(11):1324-31. PubMed ID: 14639675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
    Dewey RB; Reimold SC; O'Suilleabhain PE
    Arch Neurol; 2007 Mar; 64(3):377-80. PubMed ID: 17353380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.